Reine Nyssa J
Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA.
Clin Tech Small Anim Pract. 2007 Feb;22(1):18-25. doi: 10.1053/j.ctsap.2007.02.003.
Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD, Bristol-Myers Squibb, New York) has been the most commonly used treatment for medical management. Its use is complicated and comes with many potential side effects, making many practitioners wary of its use. Recently, trilostane has been proven to be an effective treatment of pituitary-dependent hyperadrenocorticism and is approved for use in other countries. Treatment with trilostane is somewhat simpler and the incidence of side effects seems to be less when compared with mitotane therapy. Either treatment can be a safe and effective method of treatment for pituitary-dependent hyperadrenocorticism when the practitioner and client are well educated regarding their use and an appropriate monitoring protocol is used.
垂体依赖性肾上腺皮质功能亢进是美国犬类常见的内分泌疾病。一旦确诊，必须决定是否进行治疗，如果进行治疗，应使用哪种药物。从历史上看，米托坦（Lysodren，邻对滴滴滴，百时美施贵宝公司，纽约）一直是药物治疗中最常用的药物。其使用复杂且有许多潜在副作用，这使得许多从业者对其使用持谨慎态度。最近，曲洛司坦已被证明是治疗垂体依赖性肾上腺皮质功能亢进的有效药物，并在其他国家获得批准使用。与米托坦治疗相比，曲洛司坦治疗相对简单，副作用发生率似乎更低。当从业者和客户对其使用有充分了解并采用适当的监测方案时，这两种治疗方法都可以是治疗垂体依赖性肾上腺皮质功能亢进的安全有效方法。
